RU96110213A - GRANULAR PHARMACEUTICAL DRUG - Google Patents

GRANULAR PHARMACEUTICAL DRUG

Info

Publication number
RU96110213A
RU96110213A RU96110213/14A RU96110213A RU96110213A RU 96110213 A RU96110213 A RU 96110213A RU 96110213/14 A RU96110213/14 A RU 96110213/14A RU 96110213 A RU96110213 A RU 96110213A RU 96110213 A RU96110213 A RU 96110213A
Authority
RU
Russia
Prior art keywords
pharmaceutical preparation
powder
granular pharmaceutical
finely ground
ebslen
Prior art date
Application number
RU96110213/14A
Other languages
Russian (ru)
Other versions
RU2143898C1 (en
Inventor
Накагами Хироаки
Кесикава Такетоси
Original Assignee
Дайити Фармасьютикал Ко., Лтд.
Filing date
Publication date
Application filed by Дайити Фармасьютикал Ко., Лтд. filed Critical Дайити Фармасьютикал Ко., Лтд.
Priority claimed from PCT/JP1993/001553 external-priority patent/WO1995011674A1/en
Publication of RU96110213A publication Critical patent/RU96110213A/en
Application granted granted Critical
Publication of RU2143898C1 publication Critical patent/RU2143898C1/en

Links

Claims (9)

1. Гранулированный фармацевтический препарат, полученный в результате гранулирования тонко измельченного порошка Эбселена (2-фенил-1,2-бензизоселеназол-3(2Н)-она) с использованием гидрофильного полимера.1. A granular pharmaceutical preparation obtained by granulating finely ground Ebselen powder (2-phenyl-1,2-benzisoselenazole-3 (2H) -one) using a hydrophilic polymer. 2. Водная суспензия, отличающаяся тем, что содержит тонко измельченный порошок Эбселена (2-фенил-1,2-бензиэоселеназол-3(2Н)-она) и гидрофильный полимер. 2. An aqueous suspension, characterized in that it contains finely ground Ebslen powder (2-phenyl-1,2-benzieoselenazole-3 (2H) -one) and a hydrophilic polymer. 3. Гранулированный фармацевтический препарат по п. 1, отличающийся тем, что средний размер частиц указанного тонко измельченного порошка Эбселена составляет 50 мкм или менее. 3. A granular pharmaceutical preparation according to claim 1, characterized in that the average particle size of said finely ground Ebslen powder is 50 μm or less. 4. Гранулированный фармацевтический препарат по п. 1, отличающийся тем, что средний размер указанного тонко измельченного порошка Эбселена составляет 10 мкм и менее. 4. The granular pharmaceutical preparation according to claim 1, characterized in that the average size of said finely ground Ebslen powder is 10 μm or less. 5. Гранулированный фармацевтический препарат по п. 3 иди 4, отличающийся тем, что размер частиц указанного фармацевтического препарата составляет величину 50 - 2000 мкм. 5. The granular pharmaceutical preparation according to claim 3, go 4, characterized in that the particle size of said pharmaceutical preparation is between 50 and 2000 microns. 6. Гранулированный фармацевтический препарат по п. 5, отличающийся тем, что указанный гидрофильный полимер используют в количестве от 0,5 до 100 % по весу в расчете на Эбселен. 6. The granular pharmaceutical preparation of claim 5, wherein said hydrophilic polymer is used in an amount of from 0.5 to 100% by weight based on Ebselin. 7. Водная суспензия по п. 2, отличающаяся тем, что средний размер частиц указанного тонко измельченного порошка Эбселена составляет 50 мкм или менее. 7. An aqueous suspension according to claim 2, characterized in that the average particle size of said finely ground Ebslen powder is 50 μm or less. 8. Водная суспензия по п.2, отличающаяся тем, что средний размер части указанного тонко измельченного порошка Эбселена составляет 10 мкм или менее. 8. The aqueous suspension according to claim 2, characterized in that the average particle size of said finely ground Ebslen powder is 10 μm or less. 9. Водная суспензия по п.2, отличающаяся тем, что гранулированный фармацевтический препарат по пункту 6 суспендирован в воде иди в водном растворе. 9. The aqueous suspension according to claim 2, characterized in that the granular pharmaceutical preparation according to paragraph 6 is suspended in water, go in an aqueous solution.
RU96110213/14A 1993-10-27 1993-10-27 Granulated pharmaceutical preparation and aqueous suspension based on this preparation RU2143898C1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1993/001553 WO1995011674A1 (en) 1992-04-28 1993-10-27 Granular preparation

Publications (2)

Publication Number Publication Date
RU96110213A true RU96110213A (en) 1998-08-10
RU2143898C1 RU2143898C1 (en) 2000-01-10

Family

ID=14070606

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96110213/14A RU2143898C1 (en) 1993-10-27 1993-10-27 Granulated pharmaceutical preparation and aqueous suspension based on this preparation

Country Status (6)

Country Link
US (1) US6335036B1 (en)
AT (1) ATE190487T1 (en)
DE (1) DE69328128T2 (en)
DK (1) DK0729756T3 (en)
ES (1) ES2145065T3 (en)
RU (1) RU2143898C1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3457300A (en) 1999-03-31 2000-10-16 Daiichi Pharmaceutical Co., Ltd. Substrates for thioredoxin reductase
US20050191357A1 (en) * 2002-03-20 2005-09-01 Yoshiaki Kawashima Method of manufacturing chemical-containing composite particles
JP5503879B2 (en) * 2008-02-28 2014-05-28 参天製薬株式会社 Preventive or therapeutic agent for eye diseases associated with optic neuropathy
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
WO2023240092A1 (en) * 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Ebselen containing oral dosage forms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3027073C2 (en) 1980-07-17 1985-03-07 A. Nattermann & Cie GmbH, 5000 Köln Pharmaceutical preparations containing 2-phenyl-1,2-benzisoselenazol-3 (2H) -one
DE3027075A1 (en) 1980-07-17 1982-02-18 A. Nattermann & Cie GmbH, 5000 Köln BENZISOSELENAZOLONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DK150008C (en) * 1981-11-20 1987-05-25 Benzon As Alfred PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION
DE3226284A1 (en) 1982-07-14 1984-01-19 A. Nattermann & Cie GmbH, 5000 Köln NEW BENZISOSELENAZOLONES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
JPS5942313A (en) * 1982-09-01 1984-03-08 Teijin Ltd Pharmaceutical preparation using polyvinyl pyrrolidone
DE3407511A1 (en) 1984-03-01 1985-09-05 A. Nattermann & Cie GmbH, 5000 Köln BENZISOSELENAZOLTHIONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DE3616923A1 (en) 1986-05-20 1987-11-26 Nattermann A & Cie NEW PHARMACEUTICAL USE OF 2-PHENYL-1,2-BENZISOSELENAZOLE-3 (2H) -ON
DE3620674A1 (en) * 1986-06-20 1987-12-23 Nattermann A & Cie Ointment for the treatment of skin diseases
JPH0755905B2 (en) 1986-07-17 1995-06-14 第一製薬株式会社 Liver disease treatment agent
US4778814A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
DE3720493A1 (en) * 1987-06-20 1989-01-26 Nattermann A & Cie MEDICINAL PREPARATIONS WITH MICRONIZED EBSELEN CRYSTALS
JPS6413522A (en) 1987-07-08 1989-01-18 Ricoh Kk Liquid crystal display device
DE3821392A1 (en) 1988-06-24 1989-12-28 Nattermann A & Cie NEW PHARMACEUTICAL USE OF 2-PHENYL-1,2-BENZISOSELENAZOLE-3 (2H) -ONEONE (EBSELEN)
DE3827093A1 (en) * 1988-08-10 1990-02-15 Nattermann A & Cie METHOD FOR THE PRODUCTION OF HIGH PURE PLEASURE
US5288734A (en) * 1988-10-29 1994-02-22 A. Nattermann & Cie Gmbh Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same
DE4024885C2 (en) 1990-08-06 2002-07-18 Nattermann A & Cie Use of 2-phenyl-1,2-benzisoselenazol-3 (2H) -one
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
DE59707550D1 (en) * 1996-08-27 2002-07-25 Nattermann A & Cie Pharmaceutical preparation containing 2-phenyl-1,2-benzoisoelenazol-3 (2H) -one for the treatment of Alzheimer's disease

Similar Documents

Publication Publication Date Title
KR100209175B1 (en) Pharmaceutical composition for rapid suspension in water
Sezer et al. Release characteristics of chitosan treated alginate beads: II. Sustained release of a low molecular drug from chitosan treated alginate beads
JP4129995B2 (en) Pharmaceutical composition for rapid suspension in an aqueous medium
JPS6452606A (en) Porous spherical silica and manufacture
CA2012382A1 (en) Agrochemical or biocidal suspensions
MX168893B (en) DISPERSIBLE GRANULES IN WATER AND PROCEDURE FOR ITS PREPARATION
NZ216062A (en) Method of making a drug microcapsule formulation
DK0635261T3 (en) Coated microparticles with improved drug absorption
KR840000226A (en) Manufacturing method of new type of medicine
RU96110213A (en) GRANULAR PHARMACEUTICAL DRUG
DE3860967D1 (en) DRUGS IN THE FORM OF STABLE SUSPENDERS OF FREE SUCRALFATE SUSPENSIONS.
Madan et al. Clofibrate microcapsules: preparation and release rate studies
Cakiryildiz et al. Dissolution studies with a multichannel continuous‐flow apparatus
JPS60238139A (en) Preparation of microcapsule
DE69328128T2 (en) GRANULAR PREPARATION
KR960705562A (en) Granular preparation
RU2002103512A (en) PHARMACEUTICAL PRODUCT
Gregory Stability and Flocculation of Colloidal Particles--Part 1
TH8591EX (en) Suspensions of agrochemicals or living organisms and the preparation of these suspensions.
Svetlov et al. Effect of Solidification Rate on the Long-Term Strength and Structure of the Directional Eutectic gamma/ gamma'--MeC
JPS5629517A (en) Nutrient
Lukin et al. Polyacrolein Latexes: Synthesis, Filling and Formation Mechanisms
MICROSPHERES FORMULATION AND EVALUATION OF FELODIPINE HOLLOW MICROSPHERES
Kitamura et al. Virus-like Particles in the Human Vestibular Ganglion Cells
IE45260L (en) Particulate medicament